Investigators report Phase 3 Lymphoseek results at ASCO

Independent investigators at the annual meeting of ASCO reported full results from the NEO3-09 study, reaffirming earlier top-line results that showed Neoprobe’s (AMEX:NEOP) Lymphoseek met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures. NEO3-09 is intended to be the final Phase 3 study for [...]

Synta’s ganetespib shows activity in lung cancer

Synta Pharmaceuticals (NASDAQ:SNTA) has presented results at the annual meeting of ASCO from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer that showed promising clinical activity in patients with progressive disease. Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) currently being studied in a broad [...]

Encouraging incremental data by Canadians at ASCO

Dundee Securities summed up some of the Canadian data presented at this year’s clinical oncology conference by AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ), OncoGenex (NASDAQ:OGXI), Tekmira (TSX:TKM) and MethylGene (TSX:MYG) as “encouraging, but mainly incremental.” Nevertheless, analyst David Martin downgraded MethylGene to “neutral” from “buy,” without a price target. While he called data from the company’s MGCD265 [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]